Physician profile
Manish Shah
NPI 1902001936
$526.76
in general payments reported to CMS, 2019-2025
14 companies · $16.07 in 2025
The $16.07 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2021: $17.40 · 2022: $172 · 2023: $139 · 2024: $24.28 · 2025: $16.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $149.06 | 2022-2024 | Octrode, Penta |
| Merck Sharp & Dohme LLC | $137.68 | 2019-2022 | |
| Glaxosmithkline, LLC. | $40.28 | 2022 | |
| Boston Scientific Corporation | $28.94 | 2023 | Spectra Wavewriter |
| Bayer Healthcare Pharmaceuticals INC. | $25.62 | 2023 | |
| Novo Nordisk INC | $21.79 | 2022 | |
| Pfizer INC. | $20.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.41 | 2022 | |
| Scilex Pharmaceuticals INC. | $18.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.64 | 2023 | Farxiga |
| Dexcom, INC. | $17.40 | 2021 | |
| Sumitomo Pharma America, INC. | $16.07 | 2025 | Gemtesa |
| Abbvie INC. | $14.71 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.